Sitagliptin (Januvia) for type 2 diabetes

Medical Letter on Drugs and Therapeutics

Volumn 49, Issue 1251, 2007, Pages 1-3

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; RIOMET; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ADENOSINE DEAMINASE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLYCOPROTEIN; GLYCOSYLATED HEMOGLOBIN; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

BODY WEIGHT; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SYNTHESIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOSINE DEAMINASE; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; PROTEASE INHIBITORS; PYRAZINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TRIAZOLES;

EID: 34548022949     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47:45.
2. GA Herman et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91:4612.
3. I Raz et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564.
4. P Aschner et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29:2632.
5. DM Nathan et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29:1963.
6. B Charbonnel et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638.
7. PP Stein et al. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Late-breaking abstract presented at 66th Annual Meeting of the American Diabetes Association, Washington DC, June 2006.
8. J Rosenstock et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556.
9. DJ Drucker and MA Nauck. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696.